Biology:Ubiquitin-conjugating enzyme

From HandWiki
Revision as of 22:05, 9 February 2024 by CodeMe (talk | contribs) (link)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Ubiquitin—protein ligase
Identifiers
EC number6.3.2.19
CAS number74812-49-0
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
Ubiquitin-conjugating enzyme, E2
Identifiers
SymbolUBQ-conjugat_E2
PfamPF00179
InterProIPR000608
SMARTSM00212
PROSITEPDOC00163
Membranome241

Ubiquitin-conjugating enzymes, also known as E2 enzymes and more rarely as ubiquitin-carrier enzymes, perform the second step in the ubiquitination reaction that targets a protein for degradation via the proteasome. The ubiquitination process covalently attaches ubiquitin, a short protein of 76 amino acids, to a lysine residue on the target protein. Once a protein has been tagged with one ubiquitin molecule, additional rounds of ubiquitination form a polyubiquitin chain that is recognized by the proteasome's 19S regulatory particle, triggering the ATP-dependent unfolding of the target protein that allows passage into the proteasome's 20S core particle, where proteases degrade the target into short peptide fragments for recycling by the cell.[1]

Relationships

A ubiquitin-activating enzyme, or E1, first activates the ubiquitin by covalently attaching the molecule to its active site cysteine residue. The activated ubiquitin is then transferred to an E2 cysteine. Once conjugated to ubiquitin, the E2 molecule binds one of several ubiquitin ligases or E3s via a structurally conserved binding region. The E3 molecule is responsible for binding the target protein substrate and transferring the ubiquitin from the E2 cysteine to a lysine residue on the target protein.[1]

A particular cell usually contains only a few types of E1 molecule, a greater diversity of E2s, and a very large variety of E3s. In humans, there are about 30 E2s which can bind with one of the 600+ E3s.[2] The E3 molecules responsible for substrate identification and binding are thus the mechanisms of substrate specificity in proteasomal degradation. Each type of E2 can associate with many E3s.[3]

E2s can also be used to study protein folding mechanisms. Since the ubiquitylation system is shared across all organisms, studies can use modified E2 proteins in order to understand the overall system for how all organisms process proteins.[4] There are also some proteins which can act as both and E2 and an E3 containing domains which cover both E2 and E3 functionality.[5]

Isozymes

The following human genes encode ubiquitin-conjugating enzymes:

  • UBE2A
  • UBE2B
  • UBE2C
  • UBE2D1, UBE2D2, UBE2D3, UBE2D4 (the latter putative)
  • UBE2E1, UBE2E2, UBE2E3
  • UBE2F (putative)
  • UBE2G1, UBE2G2
  • UBE2H
  • UBE2I
  • UBE2J1, UBE2J2
  • UBE2K
  • UBE2L3, UBE2L6; (UBE2L1, UBE2L2, UBE2L4 are pseudogenes)
  • UBE2M
  • UBE2N
  • UBE2O
  • UBE2Q1, UBE2Q2
  • UBE2R1 (CDC34), UBE2R2
  • UBE2S
  • UBE2T (putative)
  • UBE2U (putative)
  • UBE2V1, UBE2V2
  • UBE2W (putative)
  • UBE2Z
  • ATG3
  • BIRC6
  • UFC1


See also

References

  1. 1.0 1.1 "The ubiquitin-proteasome system". Journal of Biosciences 31 (1): 137–155. March 2006. doi:10.1007/BF02705243. PMID 16595883. 
  2. "Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex". PLOS Pathogens 16 (10): e1008784. October 2020. doi:10.1371/journal.ppat.1008784. PMID 33108402. 
  3. "Protein interaction analysis of SCF ubiquitin E3 ligase subunits from Arabidopsis". The Plant Journal 34 (6): 753–767. June 2003. doi:10.1046/j.1365-313X.2003.01768.x. PMID 12795696. 
  4. "Decoding the messaging of the ubiquitin system using chemical and protein probes" (in English). Cell Chemical Biology 28 (7): 889–902. July 2021. doi:10.1016/j.chembiol.2021.03.009. PMID 33831368. 
  5. "E2-E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877 (2): 188679. March 2022. doi:10.1016/j.bbcan.2022.188679. PMID 35074437. 

External links